MetaCap

Evommune (EVMN) vs ARS Pharmaceuticals (SPRY)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

ARS Pharmaceuticals (SPRY) has outperformed Evommune (EVMN) over the past year, losing 61.0% versus a loss of 62.4%. ARS Pharmaceuticals is the larger company by market cap ($297.6 million vs $291.1 million), about 1.0 times the size, while Evommune is growing revenue faster (+85.7% vs -5.5%). ARS Pharmaceuticals converts more of its revenue into profit, with a net margin of -203.3% versus -529.8%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

EVMN-62.37%SPRY-61.00%
+79%-0%-80%
Nov 21, 20251 yearNov 20, 2026
EVMN-61.76%SPRY-66.55%
+79%-0%-79%
Nov 3, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

EVMN versus SPRY key metrics
MetricEVMNSPRY
Share price$7.04$2.96
Market cap$291.10M$297.56M
1-day change-2.76%-11.90%
YTD return-58.88%-74.59%
1-year return-62.37%-61.00%
5-year return—-58.83%
EPS (TTM)$-3.83$-2.01
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$13.00M$84.28M
Revenue growth (YoY)+85.71%-5.46%
Net income (latest FY)$-68.87M$-171.30M
Operating margin-623.62%-212.92%
Net margin-529.77%-203.25%
52-week high$33.20$13.15
52-week low$4.94$2.44
Distance from 52-week high-78.80%-77.49%
Analyst consensusbuystrong_buy
Avg. price target upside+210.94%+474.32%
Average volume841.65K1.83M
Shares outstanding41.35M100.53M
Employees48203
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ARS Pharmaceuticals is more profitable, keeping -203.3 cents of every revenue dollar as net income versus -529.8 cents for Evommune.
  • Evommune grew revenue faster in its latest fiscal year (+85.71% vs -5.46%).

About Evommune

EVMN stock →

Evommune, Inc. operates as a clinical-stage biotechnology company in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees

About ARS Pharmaceuticals

SPRY stock →

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis.

Health Care · Biotechnology: Pharmaceutical Preparations · 203 employees

EVMN vs SPRY FAQ

Which is bigger, Evommune or ARS Pharmaceuticals?

ARS Pharmaceuticals (SPRY) is larger, with a market capitalization of $297.56M compared with $291.10M for Evommune (EVMN).

Which stock has performed better over the past year, EVMN or SPRY?

SPRY returned -61.00% over the past 12 months, compared with -62.37% for EVMN (price return, excluding dividends). Past performance does not predict future results.

Are Evommune and ARS Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons